- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01266044
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acupuncture is a technique that may treat symptoms by inserting very thin, solid, sterile, stainless steel needles into the skin at specific points.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the roll of a dice) into 1 of 3 groups.
Group 1 will receive acupuncture during the radiation treatment period.
Group 2 will receive acupuncture at different points on the body than those in Group 1 during the radiation treatment period.
You will not know if you are assigned to Group 1 or 2.
Group 3 will receive standard care without any kind of acupuncture during the radiation treatment period.
Study Visits:
If you are in Group 1 and 2, you will receive up to 21 acupuncture treatments with no more than 3 treatments per week during your regularly scheduled radiotherapy visits. It will take about 20 minutes to complete the acupuncture session each time.
No matter which group you are assigned to, you will complete the following at the middle and end of radiotherapy treatment, and again 2-4, 5-9, 10-15 months after radiotherapy treatment is complete:
- Your vital signs will be recorded.
- You will be asked about any drugs you are taking.
- You will complete 9 questionnaires about your dry mouth, quality of life, and mood. It should take about 30 minutes in total to complete the questionnaires. If you are not able to complete the questionnaires during your regularly scheduled visits, you will be able to take the questionnaires home to complete them and will be given a postage-paid return envelope to mail them back to the study doctor.
- A saliva sample will be collected to measure the quality and amount of saliva produced during radiotherapy.
- You will complete a form about your oral hygiene that should take about 5 minutes to complete.
Length of Study:
You will remain on study for up to 17 months.
Additional Information:
After your participation on this study is complete and you are no longer enrolled in this study, if you were in Group 2 or 3, you will be offered to receive 3 acupuncture treatments.
This is an investigational study.
Up to 435 patients will take part in this multicenter study. Up to 193 will be enrolled at MD Anderson.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Fudan University Cancer Hospital
-
-
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years of age and be able to give informed consent.
- Diagnosed with head and neck cancer, which will be primarily oropharyngeal, and scheduled to undergo IMRT with or without concurrent chemotherapy at M. D. Anderson.
- Treatment plan that includes external beam radiation at a mean dose of at least 24 Gy or more to one of the parotid glands (the other gland can receive less than 24 Gy).
- Anatomically intact parotid and submandibular glands.
- Karnofsky performance status > 60.
Exclusion Criteria:
- History of xerostomia prior to head and neck radiation therapy or history of Sjögren's disease or another underlying systemic illness known to cause xerostomia.
- Prior head and neck radiation treatment.
- Suspected or confirmed physical closure of salivary gland ducts on either side.
- Known bleeding disorders or taking any dose of warfarin or heparin.
- Upper or lower extremity deformities that could interfere with accurate acupoint location or alter the energy pathway as defined by traditional acupuncture theory.
- Local skin infections at or near the acupuncture sites or active systemic infection.
- History of cerebrovascular accident or spinal cord injury since the mechanism of acupuncture may be associated with central nervous system activity.
- Mental incapacitation or significant emotional or psychiatric disorder that, in the opinion of the investigator, precludes study entry as these patients may not be able to cooperate with this slightly invasive procedure or with the data collection process.
- Current acknowledged use of any illicit drugs or evidence of alcohol abuse as defined by The American Psychiatric Association criteria.
- Current acknowledged use of amifostine, cholinergic agonist medications (pilocarpine, cevimeline), certain beta adrenergic antagonists, anticholinergic agents, or any saliva substitute or other medication/herbal preparation known to affect salivary function (see Appendix F).
- Patients who are currently receiving acupuncture for any condition or if they have ever had acupuncture before.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acupuncture - Group 1
Acupuncture at 14 points.
The needles will remain in place for 20 minutes with each treatment.
Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
|
Acupuncture at 14 points.
The needles will remain in place for 20 minutes with each treatment.
Standard oral care recommendations.
Participants in all groups will receive the same recommendations.
Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
|
Active Comparator: Acupuncture - Group 2
Acupuncture needles placed at different points from Group 1.
The needles will remain in place for 20 minutes with each treatment.
Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
|
Standard oral care recommendations.
Participants in all groups will receive the same recommendations.
Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
Acupuncture needles placed at different points from Group 1.
The needles will remain in place for 20 minutes with each treatment.
|
Other: Standard Care
Standard oral care recommendations.
Participants in all groups will receive the same recommendations.
Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
|
Standard oral care recommendations.
Participants in all groups will receive the same recommendations.
Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Reported Xerostomia Symptoms Using the Xerostomia Questionnaire (XQ)
Time Frame: 4 weeks
|
Xerostomia Questionnaire (XQ), an 8-item questionnaire where subjects rate each symptom on an 11-point ordinal Likert scale from 0 to 10, with higher scores indicating greater dryness or discomfort due to dryness.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lorenzo Cohen, PHD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-0584
- NCI-2011-00306 (Registry Identifier: NCI CTRP)
- R01CA148707-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head And Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Acupuncture - Group 1
-
Beijing Hospital of Traditional Chinese MedicineUnknownSubjective Cognitive Decline | Subjective Cognitive ComplaintChina
-
Guang'anmen Hospital of China Academy of Chinese...Unknown
-
Dana-Farber Cancer InstituteThe Comprehensive and Integrative Medicine Institute of South KoreaCompletedStage I Breast Cancer | Stage II Breast Cancer | Early-Stage Breast Carcinoma | Stage III Breast Cancer | Chemotherapy-induced Peripheral Neuropathy (CIPN) | Taxane-induced Peripheral NeuropathyUnited States
-
China Medical University HospitalUnknown
-
The Third Affiliated hospital of Zhejiang Chinese...Recruiting
-
Shanghai Institute of Acupuncture, Moxibustion...CompletedCrohn's Disease | CAMChina
-
Albert Einstein College of MedicinePatient-Centered Outcomes Research Institute; Montefiore Medical Center; Mount... and other collaboratorsCompletedOsteoarthritis | Back Pain | Chronic Pain | Neck PainUnited States
-
US Department of Veterans AffairsCompletedSleep Initiation and Maintenance Disorders | Stress Disorders, Post-TraumaticUnited States
-
Charite University, Berlin, GermanyCompleted
-
Kahramanmaras Sutcu Imam UniversityCompletedPain | Interleukin | Vessels; VaricoseTurkey